Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants
October 10, 2018 16:01 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
October 05, 2018 08:10 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
October 04, 2018 16:01 ET
|
Histogenics Corporation
WALTHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to...
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
September 26, 2018 16:05 ET
|
Histogenics Corporation
WALTHAM, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
September 05, 2018 05:00 ET
|
Histogenics Corporation
‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After...
Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results
August 09, 2018 06:30 ET
|
Histogenics Corporation
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒‒ Expansion of...
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer
July 31, 2018 08:00 ET
|
Histogenics Corporation
WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset...
Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018
July 26, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored...
Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference
July 25, 2018 16:15 ET
|
Histogenics Corporation
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee
July 23, 2018 08:30 ET
|
Histogenics Corporation
WALTHAM, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...